NYSE: CBTCabot Corp Stock
$88.31-1.10 (-1.23%)
Updated Jan 24, 2025
CBT Price
$88.31
Fair Value Price
N/A
Market Cap
$4.80B
52 Week Low
$70.63
52 Week High
$117.46
P/E
13.01x
P/B
3.37x
P/S
1.54x
PEG
1.18x
Dividend Yield
1.43%
Revenue
$3.99B
Earnings
$380.00M
Gross Margin
24%
Operating Margin
14.32%
Profit Margin
9.5%
Debt to Equity
1.51
Operating Cash Flow
$692M
Beta
1.26
Next Earnings
Feb 3, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CBT Overview
Cabot Corporation manufactures a variety of chemicals and chemical-based products. Its reinforcement materials segment sells rubber-grade carbon black products used in hoses and belts in automobiles. Other segments are performance chemicals, purification solutions, and specialty fluids. Cabot was founded in 1882 and is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CBT's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Value
C
Growth
C
Momentum
C
Sentiment
B
Safety
A
Financials
A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Specialty Chemical
Industry Rating
B
CBT
Ranked#6 of 53
Ranked#6 of 53
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.92 | A | |
| $497.22 | A | |
| $42.71 | A |
Be the first to know about important CBT news, forecast changes, insider trades & much more!
CBT News
Overview
Due Diligence Score
–
Industry Average (37)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CBT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CBT ($88.31) is trading above its intrinsic value of $60.76, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CBT is good value based on its earnings relative to its share price (13.01x), compared to the US market average (30.33x)
P/E vs Market Valuation
CBT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CBT due diligence checks available for Premium users.
Valuation
CBT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
13.01x
Industry
29.84x
Market
30.33x
CBT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CBT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CBT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.37x
Industry
3.32x
CBT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CBT price to earnings growth (PEG)
For valuing profitable companies with growth potential
CBT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
CBT's financial health
Profit margin
Revenue
$1.0B
Net Income
$137.0M
Profit Margin
13.7%
CBT's Earnings (EBIT) of $572.00M... subscribe to Premium to read more.
Interest Coverage Financials
CBT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.7B
Liabilities
$2.1B
Debt to equity
1.51
CBT's short-term assets ($1.61B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBT's short-term assets ($1.61B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CBT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$204.0M
Investing
-$89.0M
Financing
-$89.0M
CBT's operating cash flow ($692.00M)... subscribe to Premium to read more.
Debt Coverage Financials
CBT vs Specialty Chemical Stocks
Cabot Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.